Change a single amino acid in a fifteen-residue chain and you can end up with a molecule that behaves nothing like the original — which is why a peptide's identity isn't really its name, it's its sequence. Two products marketed under similar names can be structurally unrelated if even one residue differs, and it's the sequence, not the label, that determines how a compound behaves in a research model.
How a peptide chain is built
Amino acids link together through peptide bonds — a condensation reaction between the carboxyl group of one amino acid and the amino group of the next, releasing a water molecule at each junction. By convention, a sequence is always written starting from the free amino group (the N-terminus) and ending at the free carboxyl group (the C-terminus), so the order in which residues are listed corresponds to the actual chemical order of the chain.
Reading sequence notation
Sequences are commonly written using three-letter amino acid codes (Gly for glycine, Pro for proline, and so on), or more compactly using single-letter codes. BPC-157, for example, is written as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val — fifteen residues, each abbreviation representing one amino acid, in the exact order they appear in the chain from N- to C-terminus. Some research peptides also include modifications outside the standard twenty amino acids — D-amino acid substitutions, cyclic structures formed by disulfide bridges, or non-natural side chains engineered for stability — all of which are part of the sequence's full identity and should be reflected in supplier documentation.
Why sequence is the identity test
A peptide's molecular formula and molecular weight are direct mathematical consequences of its sequence — every residue contributes a known, fixed mass. That's what makes mass spectrometry such a powerful identity check: by measuring the intact molecule's mass and comparing it against the mass predicted by the stated sequence, a lab can confirm — or rule out — that the material matches its labeling, independent of any purity measurement. Purity and identity are answered by different tests, and a legitimate Certificate of Analysis reports both rather than treating a purity percentage as sufficient on its own.
Sequence differences that matter in practice
Within the research peptide space, sequence-level distinctions explain why closely related compounds are studied as genuinely different research tools — for instance, why tirzepatide's sequence gives it activity at both the GIP and GLP-1 receptors, while semaglutide's sequence restricts it to GLP-1 alone (see our incretin receptor guide for the receptor biology behind that difference). The sequence is the variable that actually defines the compound; everything else — purity, formulation, packaging — describes how faithfully a given vial reproduces it.
Why product names alone aren't reliable
A compound name is a convenient label, but it isn't a chemical guarantee — nothing stops a listing from using a familiar name while describing material that hasn't actually been sequence-verified against it. That's precisely the gap that identity testing closes. Treating the sequence, not the name on the listing, as the actual specification is the more rigorous habit, and it's why documentation that states the sequence explicitly is worth more than a product title alone, however well-established that name is in the literature.
Research Use Only. Supplied strictly for laboratory research and development — not for human or veterinary use, consumption, or any therapeutic or diagnostic purpose. This article is research education, not usage guidance.